These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34009629)

  • 41. Clinically relevant mutations in the ABCG2 transporter uncovered by genetic analysis linked to erythrocyte membrane protein expression.
    Zámbó B; Bartos Z; Mózner O; Szabó E; Várady G; Poór G; Pálinkás M; Andrikovics H; Hegedűs T; Homolya L; Sarkadi B
    Sci Rep; 2018 May; 8(1):7487. PubMed ID: 29749379
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Accumulation of protoporphyrin IX in medulloblastoma cell lines and sensitivity to subsequent photodynamic treatment.
    Briel-Pump A; Beez T; Ebbert L; Remke M; Weinhold S; Sabel MC; Sorg RV
    J Photochem Photobiol B; 2018 Dec; 189():298-305. PubMed ID: 30445362
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The association between genetic polymorphisms in ABCG2 and SLC2A9 and urate: an updated systematic review and meta-analysis.
    Lukkunaprasit T; Rattanasiri S; Turongkaravee S; Suvannang N; Ingsathit A; Attia J; Thakkinstian A
    BMC Med Genet; 2020 Oct; 21(1):210. PubMed ID: 33087043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Specific inhibition of the ABCG2 transporter could improve the efficacy of photodynamic therapy.
    Bebes A; Nagy T; Bata-Csörgo Z; Kemény L; Dobozy A; Széll M
    J Photochem Photobiol B; 2011 Nov; 105(2):162-6. PubMed ID: 21911299
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human protoporphyria: reduced cutaneous photosensitivity and lower erythrocyte porphyrin levels during pregnancy.
    Poh-Fitzpatrick MB
    J Am Acad Dermatol; 1997 Jan; 36(1):40-3. PubMed ID: 8996259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Photosensitivity, abnormal porphyrin profile, and sideroblastic anemia.
    Lim HW; Cooper D; Sassa S; Dosik H; Buchness MR; Soter NA
    J Am Acad Dermatol; 1992 Aug; 27(2 Pt 2):287-92. PubMed ID: 1517489
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria.
    Wang P; Sachar M; Lu J; Shehu AI; Zhu J; Chen J; Liu K; Anderson KE; Xie W; Gonzalez FJ; Klaassen CD; Ma X
    Sci Adv; 2019 Sep; 5(9):eaaw6127. PubMed ID: 31555729
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
    Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
    Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Common dysfunctional variants in ABCG2 are a major cause of early-onset gout.
    Matsuo H; Ichida K; Takada T; Nakayama A; Nakashima H; Nakamura T; Kawamura Y; Takada Y; Yamamoto K; Inoue H; Oikawa Y; Naito M; Hishida A; Wakai K; Okada C; Shimizu S; Sakiyama M; Chiba T; Ogata H; Niwa K; Hosoyamada M; Mori A; Hamajima N; Suzuki H; Kanai Y; Sakurai Y; Hosoya T; Shimizu T; Shinomiya N
    Sci Rep; 2013; 3():2014. PubMed ID: 23774753
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.
    Hasanabady MH; Kalalinia F
    J Biosci; 2016 Jun; 41(2):313-24. PubMed ID: 27240991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
    Karthikeyan C; Malla R; Ashby CR; Amawi H; Abbott KL; Moore J; Chen J; Balch C; Lee C; Flannery PC; Trivedi P; Faridi JS; Pondugula SR; Tiwari AK
    Cancer Lett; 2016 Jun; 376(1):118-26. PubMed ID: 27012188
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function.
    Robinson AN; Tebase BG; Francone SC; Huff LM; Kozlowski H; Cossari D; Lee JM; Esposito D; Robey RW; Gottesman MM
    Drug Metab Dispos; 2019 Jul; 47(7):715-723. PubMed ID: 31048454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
    Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
    Mol Pharm; 2019 Jul; 16(7):3040-3052. PubMed ID: 31117741
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pivotal roles of peptide transporter PEPT1 and ATP-binding cassette (ABC) transporter ABCG2 in 5-aminolevulinic acid (ALA)-based photocytotoxicity of gastric cancer cells in vitro.
    Hagiya Y; Endo Y; Yonemura Y; Takahashi K; Ishizuka M; Abe F; Tanaka T; Okura I; Nakajima M; Ishikawa T; Ogura S
    Photodiagnosis Photodyn Ther; 2012 Sep; 9(3):204-14. PubMed ID: 22959800
    [TBL] [Abstract][Full Text] [Related]  

  • 57. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
    Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
    Pharmacol Res; 2018 Nov; 137():47-55. PubMed ID: 30253203
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The ABCG2/BCRP transporter and its variants - from structure to pathology.
    Sarkadi B; Homolya L; Hegedűs T
    FEBS Lett; 2020 Dec; 594(23):4012-4034. PubMed ID: 33015850
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
    Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
    Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.